濟民製藥(603222.SH)2019年度淨利潤預增102.92%-121.64%
格隆匯1月20日丨濟民製藥(603222.SH)公佈,預計2019年年度實現歸屬於上市公司股東的淨利潤與上年同期相比增加3300萬元-3900萬元,同比增長102.92%-121.64%;
公司預計2019年年度歸屬於上市公司股東的扣除非經常性損益的淨利潤與去年同期相比增長10068萬元-10668萬元,歸屬於上市公司股東的扣除非經常性損益的淨利潤由虧損轉為盈利。
業績預增的主要原因如下:(一)公司醫療器械板塊業務收入及利潤均實現較大幅度增長;(二)公司大輸液板塊自動化升級改造完成及產品結構優化,綜合毛利率顯著提升,帶動大輸液板塊利潤增長;(三)公司處置白水濟民醫院實現投資收益;(四)公司2018年計提商譽減值12123萬元,2019年商譽減值規模較2018年大幅降低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.